Clinical Trial Update: Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial comparing safety and efficacy of T-2345 to Xalatan in primary open-angle glaucoma or ocular hypertension completed with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• T-2345
• Xalatan (latanoprost)

Snippet

Sponsor: Nephron Pharmaceuticals Corporation | Conditions: Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2018-08-22